OncoMatch/Clinical Trials/NCT05926492
A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
Is NCT05926492 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Surufatinib plus chemotherapy and Chemotherapy for osteosarcoma.
Treatment: Surufatinib plus chemotherapy · Chemotherapy — This phase II study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Osteosarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Patients who have previously received chemotherapy drugs
Cannot have received: antiangiogenic agent (surufatinib)
Patients who have previously received...surufatinib, or other antiangiogenic agents
Cannot have received: systematic anti-tumor therapy
Received approved or under development systematic anti-tumor therapy within 4 weeks before enrollment, including chemotherapy, radical radiotherapy, biological immunotherapy, targeted therapy, etc.
Lab requirements
Blood counts
Neutrophil absolute value ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin concentration ≥9g/dL
Kidney function
serum creatinine ≤1.5×ULN, creatinine clearance (CCr)≥60ml/min
Liver function
aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, total bilirubin ≤1.5×ULN; In case of liver metastasis, AST and ALT≤5×ULN
Cardiac function
LVEF (Left ventricular Ejection Fraction) < 50% [excluded]; NYHA > level 2 [excluded]; acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; ventricular arrhythmias requiring medical treatment
Blood test (without blood transfusion within 14 days) 1) Neutrophil absolute value ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin concentration ≥9g/dL); 2) Liver function test (aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, total bilirubin ≤1.5×ULN; In case of liver metastasis, AST and ALT≤5×ULN); 3) Renal function (serum creatinine ≤1.5×ULN, creatinine clearance (CCr)≥60ml/min); LVEF (Left ventricular Ejection Fraction) < 50% [excluded]; NYHA > level 2 [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05926492 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages